RecruitingPhase 2

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Immunovant Sciences GmbH · NCT07032662

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Status re-checked against ClinicalTrials.gov within the last 12 hours.

This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.

Being studied: Imeroprubart; Placebo

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Have met clinical diagnostic criteria for typical CIDP (including incomplete typical CIDP) or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of CIDP.
Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN/PNS guideline on diagnosis and treatment of CIDP.
Are currently on, and have been receiving chronic, stable doses of systemic corticosteroids (i.e., daily or every other day oral or pulse regimen), or immunoglobulin therapy (IVIg or SCIg) ± corticosteroid therapy (either low dose oral corticosteroids or pulse corticosteroids) for at least 3 months for the treatment of CIDP at the time of the Screening Visit.

Additional inclusion criteria are defined in the protocol.

Exclusion Criteria

Have current or prior history of IgM paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies.
Have distal, sensory, or focal CIDP, or have a diagnosis of autoimmune nodopathy per the EAN/PNS guideline on diagnosis and treatment of CIDP.
Have polyneuropathy of causes other than CIDP including but not limited to:

Multifocal motor neuropathy
Hereditary demyelinating neuropathy
Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS)
Lumbosacral radiculoplexus neuropathy
Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies
Drug- or toxin-induced
Have diabetes mellitus (DM) and meets any of the following criteria:

Does not have both typical CIDP and strong evidence of demyelination on nerve conduction study.
In the opinion of the Investigator, there is evidence of poorly controlled DM preceding the diagnosis of CIDP.
In the opinion of the Investigator, there is evidence of poorly controlled DM at screening.
Have a history of myelopathy or evidence of central demyelination. Additional exclusion criteria are defined in the protocol.